Canteros CE. [Paracoccidioidomycosis: Chronicle of a neglected disease]. Medicina (B Aires). 2018;78(3):180-4.

Martinez R. New trends in paracoccidioidomycosis epidemiology. J Fungi (Basel). 2017;3(1):1-13. https//doi.org/10.3390/jof3010001

Arias Ramos D, Alzate JA, Giraldo Montoya ÁM,Trujillo YA, Arias Ramos LY. Thinking in paracoccidioidomycosis: delayed diagnosis of a neglected tropical disease, case report and review of clinical reports and ecoepidemiologic data from Colombia since the 2000. BMC Infect Dis. 2020;20(1):4-9. https//doi.org/10.1186/s12879-020-4864-8.

de Arruda JAA, Schuch LF, Abreu LG, Silva LV de O, Mosconi C, Monteiro JLGC, et al. A multicentre study of oral paracoccidioidomycosis: Analysis of 320 cases and literature review. Oral Dis. 2018;24(8):1492-502. https//doi.org/10.1111/odi.12925.

Shikanai-Yasuda MA, Mendes RP, Colombo AL, de Queiroz-Telles F, Kono ASG, Paniago AMM, et al. Brazilian guidelines for the clinical management of paracoccidioidomycosis. Rev Soc Bras Med Trop. 2017;50(5):715-40. https//doi.org/10.1590/0037-8682-0230-2017

Fortes MRP, Miot HA, Kurokawa CS, Marques MEA, Marques SA. Immunology of paracoccidioidomycosis. An Bras Dermatol. 2011;86(3):516-25. https//doi.org/10.1590/s0365-05962011000300014

Shikanai-Yasuda MA, Benard G, Higaki Y et al. Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis. Med Mycol. 2002;40(4):411-7. https//doi.org/10.1080/mmy.40.4.411.4178. Queiroz-Telles F, Goldani LZ, Schlamm HT, Goodrich J, Espinel-Ingroff A, Shikanai-Yasuda M. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis. 2007;45(11):1462-9. https//doi.org/10.1086/522973